Sign in
Taking people in United StatesPhase 2

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Key facts

Who runs it
LISCure Biosciences
Where
Aurora, Baltimore, Iowa City, Nashville, Rochester, Sacramento, and Seattle, United StatesSee the 7 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
87 people, planned
Started
Nov 2025
Expected to end
Feb 2029
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • LB-P8 low-dose
  • LB-P8 high-dose
  • Placebo
Record updated
24 October 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Age: 18 to 75 years
  • A diagnosis of PSC based on cholangiographic evidence of PSC in accordance with American Association for the Study of Liver Diseases (AASLD) guidelines
  • ALP >1.5 times the ULN at screening
  • PSC with or without IBD, such as ulcerative colitis or Crohn's disease
  • If patients are being administered biologic or advanced therapeutic treatments, immunosuppressants, systemic corticosteroids, obeticholic acid, fibrates, or statins, they must be on a stable dose for ≥3 months prior to, and including, Day 0 and plan to remain on a stable dose throughout the study
  • If patients are receiving ursodeoxycholic acid, they must be on a stable dose (not exceeding 23 mg/kg/day) for >3 months prior to screening
  • Patient agrees to stop all probiotics for at least 2weeks prior to treatment
  • Patient is unable to conceive and/or patient who's partner is unable to become pregnant and/or agree to use effective methods of contraception when engaging in heterosexual intercourse

Who cannot take part

  • Treatment with any investigational agents within 3 months or 5 half-lives, whichever is longer prior to treatment or during the study. Gene therapy or other long-lasting investigational agents with unknown half-life is not allowed
  • Patients who require chronic use of antibiotics, received antibiotics in the last 1 month, or received Rebyota or Vowst (applicable for patients with Clostridioides difficile infection)
  • History of a liver transplant or anticipated need for a liver transplant within 1 year
  • Model for end-stage liver disease (MELD) score as below, unless the MELD is driven by anticoagulant therapy, vitamin deficiency, or kidney disease:
  • Any history of cholangiocarcinoma, gallbladder cancer, or hepatocellular carcinoma
  • History of any malignancy with lymph node or regional metastases within 5 years or current malignancy undergoing active treatment
  • In patients with ulcerative colitis, partial Mayo score of >6 or, patients with Crohn's disease if CDAI of >220
  • Patients with indwelling biliary drain (or stent), total proctocolectomy with ileal anal pouch, partial large bowel resections or history of small bowel resection
  • Active drug (known or suspected use of illicit drugs or drugs of abuse) or alcohol abuse disorder
  • Clinically significant and/or active infection
  • Evidence of compensated or decompensated cirrhosis based on histology, relevant medical complications, or laboratory parameters
  • Other causes of liver disease, such as autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), AIH/PSC overlap syndrome, alpha-1-antitrypsin deficiency, viral hepatitis, iron overload syndrome, Wilson disease, nonalcoholic steatohepatitis, and/or alcohol related liver disease. Additionally, positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti HCV) (detectable HCV RNA in the serum), or human immunodeficiency virus antibodies (anti HIV)
  • Subjects with a greater degree of immunosuppression, as evidenced by Alsolute neutrophil count <500 cells/mL or in the investigator's judgement immunosuppressed and at higher risk of infection
  • Patients who show evidence of significant worsening of hepatic function will be excluded
  • MELD Score of >12 (decompensated cirrhosis) for Part 1 of the study
  • MELD Score of >12 for Part 2 of the study
  • Small-duct PSC (in the absence of large duct PSC)
  • Secondary causes of sclerosing cholangitis including IgG4 associated sclerosing cholangitis
  • Chronic kidney injury
  • Recent acute cholangitis (within 90 days)
  • Female patients who are pregnant, nursing, or planning to become pregnant during the study

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • UCHealth University of Colorado HospitalAurora, United StatesContact: UCHealth University of Colorado HospitalNot yet recruiting
  • Mercy Medical CenterBaltimore, United StatesContact: Mercy Medical CenterTaking people
  • University of Iowa Hospitals and ClinicsIowa City, United StatesContact: University Of Iowa Hospitals And ClinicsTaking people
  • The Vanderbilt ClinicNashville, United StatesContact: The Vanderbilt ClinicTaking people
  • Mayo ClinicRochester, United StatesContact: Mayo ClinicNot yet recruiting
  • University of California - DavisSacramento, United StatesContact: University of California DavisNot yet recruiting
  • Liver Institute NorthwestSeattle, United StatesContact: Liver institute NorthwestTaking people

About the trial

What the trial wants to find out

The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.

The 3 groups in the trial

  • LB-P8 low-doseTreatment being tested

    Oral capsule, 1×10\^10 CFU/day

  • LB-P8 high-doseTreatment being tested

    Oral capsule, 1×10\^11 CFU/day

  • PlaceboPlacebo, for comparison

    Oral capsule, placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Study Evaluating the Safety and Efficacy of LB P8 in Patients With Primary Sclerosing Cholangitis (PSC)
Criteria questions
Built from NCT06699121, who can take part
Record updated
24 October 2025